CAS Medical Systems, Inc. Securities Litigation

If you purchased a significant amount of shares of CAS Medical Systems, Inc. (NASDAQ: CASM), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:CAS Medical Systems, Inc.
Date Filed:March 7th, 2019
Sector:Health Care
Industry:Medical/Dental Instruments

According to the Complaint, this action stems from a proposed transaction announced on February 12, 2019 (the "Proposed Transaction"), pursuant to which CAS Medical Systems, Inc. ("CAS Medical" or the "Company") will be acquired by Edwards Lifesciences Corporation and its affiliates (together, "Edwards"). On February 11, 2019, CAS Medical's Board of Directors (the "Board" or "Individual Defendants") caused the Company to enter into an agreement and plan of merger (the "Merger Agreement") with Edwards Lifesciences Holding, Inc. and Crown Merger Sub, Inc. Pursuant to the terms of the Merger Agreement, CAS Medical's stockholders will receive $2.45 in cash for each share of CAS Medical common stock they hold. On March 1, 2019, defendants filed a proxy statement (the "Proxy Statement") with the United States Securities and Exchange Commission (the "SEC") in connection with the Proposed Transaction.

The Complaint alleges the Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement false and misleading. Accordingly, plaintiff alleges that defendants violated Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "1934 Act") in connection with the Proxy Statement.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for CAS Medical Systems, Inc.

 
First Identified Complaint

Adam Franchi, et al. v. CAS Medical Systems, Inc., et al.

Date Filed:March 7th, 2019
Class Period Start:February 12th, 2019
Class Period End:March 7th, 2019
First Identified Complaint Filings
#Document TitleFiling Date